cefoxitin and Cystitis

Prophylactic effect of cefoxitin against postoperative infection at a dose of 2 g intravenous (single dose 30 minutes before the operation) was investigated using fever index in patients who underwent the elective, nonradical abdominal hysterectomy. The results obtained are summarized as follows. Total fever index values were 12.9 +/- 10.0 degree-hours in the control group (n = 39), 11.3 +/- 9.7 degree-hours in the study group (n = 39). There were no statistical significance between both groups. Data from this investigation does not suggest the concept that prophylactic antibiotics are beneficial in the reduction of postoperative infection. The results of this prospective study reflected in unnecessity of antibiotic prophylaxis in abdominal hysterectomy.

Topics: Adult; Cefoxitin; Cystitis; Female; Humans; Hysterectomy; Infection Control; Infections; Middle Aged; Parametritis; Postoperative Complications; Prospective Studies; Random Allocation; Surgical Wound Infection

Ninety-one patients were enrolled in a prospective randomized double-blind study evaluating the efficacy of systemic antibiotic prophylaxis in reducing the incidence of operative site infection after abdominal hysterectomy. Forty-five patients received a 2-dose course of cefoxitin; 46 patients received a placebo. Although patients in the antibiotic group had a lower fever index, there were no statistically significant differences between groups with respect to incidence of pelvic cellulitis, urinary tract infection, wound infection, need for therapeutic antibiotics, or duration of hospitalization. It is concluded that, in this patient population, the theoretic risks of widespread use of systemic antibiotics for prophylaxis outweigh the observed benefits.

Topics: Adult; Anti-Bacterial Agents; Cefoxitin; Clinical Trials as Topic; Cystitis; Double-Blind Method; Female; Humans; Hysterectomy; Parametritis; Postoperative Complications; Premedication; Random Allocation

This study sought to compare the antimicrobial susceptibility rates between acute uncomplicated cystitis patients with failed initial antimicrobial treatment, who were considered unresolved cases, and newly presenting acute uncomplicated cystitis patients without recent antimicrobial use within 3 months and to determine whether different treatment strategies should be applied according to recent antimicrobial exposure (RAE). Female acute uncomplicated cystitis patients with Escherichia coli growth, who visited our hospital's urology department from 2010 to 2014, were divided according to RAE. The antimicrobial susceptibility of E. coli was compared between the group with RAE and the group with no antimicrobial exposure (NAE) within 3 months. The total number of acute uncomplicated cystitis patients with E. coli growth was 259: 40 patients comprised the RAE group and 219 patients formed the NAE group. The mean age was significantly older and previous recurrent cystitis history was higher in the RAE group (p < 0.05). Furthermore, the antimicrobial susceptibility of E. coli to amoxicillin-clavulanic acid, cefotaxime, cefoxitin, ciprofloxacin, and trimethoprim-sulfamethoxazole was significantly lower in the RAE group, with susceptibility results of 64.7%/88.0% (RAE/NAE), 77.5%/89.0%, 79.4%/95.3%, 31.3%/64.2%, and 42.5%/70.6%, respectively. RAE was an independent factor for antimicrobial resistance. This study showed that antimicrobial susceptibilities were significantly lower in acute uncomplicated cystitis patients with failed initial antimicrobial treatment, who are defined as unresolved cases. Our results suggest that first-line antimicrobials might show poor efficacy in cases of unresolved, acute uncomplicated cystitis and alternative or secondary antimicrobials should be considered in these cases.

Topics: Acute Disease; Adult; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Cefotaxime; Cefoxitin; Ciprofloxacin; Cystitis; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Microbial Sensitivity Tests; Middle Aged; Recurrence; Treatment Failure; Trimethoprim, Sulfamethoxazole Drug Combination

An investigation conducted on healthy volunteers showed that cefoxitin quickly reaches high plasma concentrations, and is almost completely excreted via the urine within 6 hours. In a series of 21 cases treated with 2 g i.v. in 100 ml of a 5% glucose solution two or three times a day, a clinical cure was achieved in 20, and marked improvement in the remaining patient.

Topics: Bacillus subtilis; Bronchitis; Bronchopneumonia; Cefoxitin; Cholangitis; Cystitis; Drug Evaluation; Drug Tolerance; Gas Gangrene; Herpes Zoster; Humans; Kinetics; Osteomyelitis; Sepsis

1) Cefoxitin (CFX) was administered to seven patients: two with acute pneumonia, two with acute pyelonephritis, one with pyonephrosis complicated to pyelolithotomy, one with acute cystitis and one with CONN syndrome complicated to liver cirrhosis. 2) Response to the CFX treatment was excellent in three patients, good in three, and poor in one. 3) No side effect was observed in all cases. In two patients in whom CFX and furosemide were concomitantly administered, no aggravation of the renal function was observed.

Topics: Acute Disease; Adult; Aged; Cefoxitin; Cephalosporins; Cystitis; Drug Evaluation; Female; Humans; Male; Middle Aged; Nephrosis; Pneumonia; Pyelonephritis